Stable Funds Fuel Smithsonian's Risky Research

WASHINGTON—David Challinor smiles as he explains how Smithsonian Institution scientists benefit from about a dozen National Science Foundation grants even though Congress has prohibited the organization from asking NSF for money. "It just takes some imagination. One way is to join a consortium. Another is to approach the NSF with a project it wants done. As any Washington bureaucrat knows, there's more than one way to skin a cat." In fact, the 66-year-old Challinor knows more than most bur

Written byElisabeth Carpenter
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

"It just takes some imagination. One way is to join a consortium. Another is to approach the NSF with a project it wants done. As any Washington bureaucrat knows, there's more than one way to skin a cat."

In fact, the 66-year-old Challinor knows more than most bureaucrats about which strings to pull to advance the cause of science. This summer he will retire after 16 years as head of scientific research at the Smithsonian, which in addition to its museums runs a $60 million-a-year research program with 400 scholars and scientists in the United States and Panama. Two years ago he became Assistant Secretary for Research, adding the arts and humanities to his previous duties overseeing science.

Although some of the proposals that Challinor approves relate to collections from the Institution's 12 museums—the Museum of Natural History's fish collection has enabled researchers to trace heavy metals in the environment ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies